Hansoh Pharmaceutical Group Co Ltd
3KY
Company Profile
Business description
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
Contact
No. 287 Xiangke Road
Pudong New Area
Shanghai
CHNT: +86 4008285227
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
9,347
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.80 | 11.30 | -0.13% |
| CAC 40 | 7,756.49 | 54.77 | -0.70% |
| DAX 40 | 25,224.72 | 147.03 | -0.58% |
| Dow JONES (US) | 52,867.98 | 11.89 | 0.02% |
| FTSE 100 | 10,696.81 | 28.22 | -0.26% |
| HKSE | 23,106.19 | 171.51 | 0.75% |
| NASDAQ | 26,008.86 | 694.00 | -2.60% |
| Nikkei 225 | 62,693.16 | 214.68 | -0.34% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,663.43 | 93.74 | -1.21% |
| S&P/ASX 200 | 8,795.20 | 2.00 | 0.02% |
| SSE Composite Index | 3,690.48 | 32.45 | 0.89% |